[Click e-Stock] Yuhan Corporation Expected to See Full-Fledged Royalty Inflows... Target Price Set at 125,000 Won
KB Securities Has High Expectations for Yuhan Corporation's Leclaza
Recommends "Buy" Rating
On May 28, KB Securities initiated coverage on Yuhan Corporation, giving it a "Buy" investment opinion and a target price of 125,000 won, stating that the company is expected to enter a phase where royalty inflows will be fully realized.
Jihoon Shin, an analyst at KB Securities, commented, "Yuhan Corporation is benefiting from several positive factors, including royalty inflows from the market entry of Lazcluze (the U.S. name for Leclaza), contract development and manufacturing organization (CDMO) orders at Yuhan Chemical, sales expansion driven by capacity increase, and the highlighted value of its pipeline."
Shin further explained, "Annual sales for Lazcluze are forecast to reach 4 billion dollars by 2030, which stems from its strong clinical superiority over the competing drug Tagrisso."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, "The new allergy drug Lesigercept demonstrated a stronger and more sustained immunoglobulin E (IgE) reduction effect compared to the blockbuster drug Xolair in the Phase 1b trial. In particular, it has drawn market expectations by confirming symptom improvement even among patients with chronic spontaneous urticaria (CSU) who do not respond to Xolair."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.